| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 168.4MM | +5% |
| Gross Profit | 125.3MM | -2% |
| Cost Of Revenue | 43.2MM | +34% |
| Operating Income | 40.2MM | -38% |
| Operating Expenses | 85.1MM | +34% |
| Net Income | 26.6MM | -31% |
| R&D | 30.3MM | +73% |
| G&A | 27.9MM | +24% |
| Marketing | 26.9MM | +15% |
| Amortization | 6MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on April 30, 2024, at 8:30 a.m. ET to discuss the results.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile.
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m. ET.
Jeffrey Dierks, the Chief Commercial Officer of Harmony Biosciences Holdings Inc (NASDAQ:HRMY), has sold 11,979 shares of the company on March 15, 2024, according to a recent SEC Filing.
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Biotech Stocks with Huge Potential. Recent developments, technological as well as optimism related to interest rate reductions, have led to […]
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2023 Earnings Call Transcript February 22, 2024 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.74. Harmony Biosciences Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
HRMY vs. TECH: Which Stock Is the Better Value Option?
Q4 2023 Harmony Biosciences Holdings Inc Earnings Call